Fairscale Capital LLC Makes New Investment in Eli Lilly and Company (NYSE:LLY)

Fairscale Capital LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 547 shares of the company’s stock, valued at approximately $515,000.

Other large investors have also recently modified their holdings of the company. Capital Planning LLC purchased a new position in Eli Lilly and Company in the 1st quarter worth approximately $262,000. CHURCHILL MANAGEMENT Corp purchased a new position in shares of Eli Lilly and Company in the first quarter worth $6,916,000. M&G Plc bought a new stake in Eli Lilly and Company during the 1st quarter valued at $8,896,000. IPG Investment Advisors LLC purchased a new stake in Eli Lilly and Company during the 4th quarter valued at $351,000. Finally, HighPoint Advisor Group LLC bought a new stake in Eli Lilly and Company in the 4th quarter worth $9,878,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the transaction, the insider now owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last ninety days, insiders sold 442,229 shares of company stock worth $410,002,456. 0.13% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

LLY has been the topic of a number of analyst reports. Berenberg Bank boosted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Bank of America increased their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Barclays boosted their target price on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Finally, JPMorgan Chase & Co. raised their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $977.35.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $921.49 on Friday. Eli Lilly and Company has a twelve month low of $516.57 and a twelve month high of $972.53. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. The company has a market capitalization of $875.79 billion, a P/E ratio of 135.71, a PEG ratio of 2.79 and a beta of 0.42. The stock’s 50 day moving average is $895.06 and its 200 day moving average is $838.32.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. On average, equities research analysts predict that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Thursday, August 15th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.56%. The ex-dividend date was Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.